Many Patients With Primary Sclerosing Cholangitis and Increased Serum Levels of Carbohydrate Antigen 19-9 Do Not Have Cholangiocarcinoma

Clinical Gastroenterology and Hepatology

Volumn 9, Issue 5, 2011, Pages

  Sinakos, Emmanouil ^a   Saenger, Amy K ^a   Keach, Jill ^a   Kim, W Ray ^a   Lindor, Keith D ^a  

^a MAYO CLINIC   (United States)

Author keywords

Bile Duct; Biliary Tract Cancer; Cancer Diagnostic; Liver Disease

Indexed keywords

BILIRUBIN; CA 19-9 ANTIGEN;

ADULT; ARTICLE; BILE DUCT CARCINOMA; CHOLESTASIS; ENDOSCOPY; FEMALE; FOLLOW UP; HUMAN; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PREVALENCE; PRIMARY SCLEROSING CHOLANGITIS; RECURRENT DISEASE;

EID: 79955035338     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2011.02.007     Document Type: Article

References (30)

1. Bergquist A., Ekbom A., Olsson R., et al. Hepatic and extrahepatic malignancies in primary sclerosing cholangitis. J Hepatol 2002, 36:321-327.
2. Broome U., Olsson R., Loof L., et al. Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis. Gut 1996, 38:610-615.
3. Burak K., Angulo P., Pasha T.M., et al. Incidence and risk factors for cholangiocarcinoma in primary sclerosing cholangitis. Am J Gastroenterol 2004, 99:523-526.
4. Claessen M.M., Vleggaar F.P., Tytgat K.M., et al. High lifetime risk of cancer in primary sclerosing cholangitis. J Hepatol 2009, 50:158-164.
5. Charatcharoenwitthaya P., Enders F.B., Halling K.C., et al. Utility of serum tumor markers, imaging, and biliary cytology for detecting cholangiocarcinoma in primary sclerosing cholangitis. Hepatology 2008, 48:1106-1117.
6. Bangarulingam S.Y., Bjornsson E., Enders F., et al. Long-term outcomes of positive fluorescence in situ hybridization tests in primary sclerosing cholangitis. Hepatology 2009, 51:174-180.
7. Duffy M.J. CA 199 as a marker for gastrointestinal cancers: a review. Ann Clin Biochem 1998, 35:364-370.
8. Maestranzi S., Przemioslo R., Mitchell H., et al. The effect of benign and malignant liver disease on the tumour markers CA19-9 and CEA. Ann Clin Biochem 1998, 35:99-103.
9. Nehls O., Gregor M., Klump B. Serum and bile markers for cholangiocarcinoma. Semin Liver Dis 2004, 24:139-154.
10. Rhodes J.M. Usefulness of novel tumour markers. Ann Oncol 1999, 10(Suppl 4):118-121.
11. Torzilli G., Makuuchi M., Ferrero A., et al. Accuracy of the preoperative determination of tumor markers in the differentiation of liver mass lesions in surgical patients. Hepatogastroenterology 2002, 49:740-745.
12. Chapman R., Kalloo A., Nagorney D., et al. Diagnosis and management of primary sclerosing cholangitis (PSC). Hepatology 2010, 51:660-678.
13. Chalasani N., Baluyut A., Ismail A., et al. Cholangiocarcinoma in patients with primary sclerosing cholangitis: a multicenter case-control study. Hepatology 2000, 31:7-11.
14. Levy C., Lymp J., Angulo P., et al. The value of serum CA 199 in predicting cholangiocarcinomas in patients with primary sclerosing cholangitis. Dig Dis Sci 2005, 50:1734-1740.
15. Nichols J.C., Gores G.J., LaRusso N.F., et al. Diagnostic role of serum CA 199 for cholangiocarcinoma in patients with primary sclerosing cholangitis. Mayo Clin Proc 1993, 68:874-879.
16. Ramage J.K., Donaghy A., Farrant J.M., et al. Serum tumor markers for the diagnosis of cholangiocarcinoma in primary sclerosing cholangitis. Gastroenterology 1995, 108:865-869.
17. Siqueira E., Schoen R.E., Silverman W., et al. Detecting cholangiocarcinoma in patients with primary sclerosing cholangitis. Gastrointest Endosc 2002, 56:40-47.
18. Akdogan M., Sasmaz N., Kayhan B., et al. Extraordinarily elevated CA19-9 in benign conditions: a case report and review of the literature. Tumori 2001, 87:337-339.
19. Albert M.B., Henry J.P. Elevated serum levels of tumor markers CA 199 in acute cholangitis. Dig Dis Sci 1988, 33:1223-1225.
20. Murray M.D., Burton F.R., Di Bisceglie A.M. Markedly elevated serum CA 199 levels in association with a benign biliary stricture due to primary sclerosing cholangitis. J Clin Gastroenterol 2007, 41:115-117.
21. LaRusso N.F., Shneider B.L., Black D., et al. Primary sclerosing cholangitis: summary of a workshop. Hepatology 2006, 44:746-764.
22. Kim W.R., Therneau T.M., Wiesner R.H., et al. A revised natural history model for primary sclerosing cholangitis. Mayo Clin Proc 2000, 75:688-694.
23. Rea D.J., Heimbach J.K., Rosen C.B., et al. Liver transplantation with neoadjuvant chemoradiation is more effective than resection for hilar cholangiocarcinoma. Ann Surg 2005, 242:451-461.
24. Bjornsson E., Kilander A., Olsson R. CA 199 and CEA are unreliable markers for cholangiocarcinoma in patients with primary sclerosing cholangitis. Liver 1999, 19:501-508.
25. Hultcrantz R., Olsson R., Danielsson A., et al. A 3-year prospective study on serum tumor markers used for detecting cholangiocarcinoma in patients with primary sclerosing cholangitis. J Hepatol 1999, 30:669-673.
26. Marrelli D., Caruso S., Pedrazzani C., et al. CA19-9 serum levels in obstructive jaundice: clinical value in benign and malignant conditions. Am J Surg 2009, 198:333-339.
27. Mann D.V., Edwards R., Ho S., et al. Elevated tumour marker CA19-9: clinical interpretation and influence of obstructive jaundice. Eur J Surg Oncol 2000, 26:474-479.
28. Ong S.L., Sachdeva A., Garcea G., et al. Elevation of carbohydrate antigen 19.9 in benign hepatobiliary conditions and its correlation with serum bilirubin concentration. Dig Dis Sci 2008, 53:3213-3217.
29. Kaya M., de Groen P.C., Angulo P., et al. Treatment of cholangiocarcinoma complicating primary sclerosing cholangitis: the Mayo Clinic experience. Am J Gastroenterol 2001, 96:1164-1169.
30. Bjornsson E., Angulo P. Cholangiocarcinoma in young individuals with and without primary sclerosing cholangitis. Am J Gastroenterol 2007, 102:1677-1682.